Uloric litigation
Claims allege that the gout medication Uloric carried a significantly higher risk of cardiovascular death than the older standard treatment.
Free case review
What the claims allege
A post-marketing trial mandated by the FDA found that patients on febuxostat (Uloric) died of cardiovascular causes at a higher rate than patients on allopurinol, prompting a boxed warning in 2019. Claims allege the signal was visible in data the manufacturer held years earlier.
Injuries named in the litigation
- Cardiovascular death
- Heart attack
- Stroke
Who may qualify
If you or a family member taking Uloric suffered a heart attack, stroke, or cardiovascular death, you may have a claim. The review is free and confidential, and we will give you an honest answer either way. You pay attorney's fees only if we recover for you.
Call (888) 391‑1315 or use the form for a free, confidential review. You pay attorney's fees only if we recover for you.